EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 767 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Diving into our role in 50 top cancer drugs February 9, 2022 EMA Recommends Granting a Marketing Authorisation for Tarlatamab April 17, 2026 Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... December 5, 2024 World Cancer Day 2023: where does the UK stand? February 3, 2023 Load more HOT NEWS March is Colon Cancer Awareness Month Latest episode of our podcast for cancer researchers FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated... After Chemotherapy, Selma Blair Embraces Her Buzzed “Patchy Charcoal” Hair
